Table 4.

Inhibition of bursting by subtype-selective ligands

Ligand	Receptor(s) activated	% inhibition of burst rate	Number of slices
SST	All	58.6 ± 4%	11
Octreotide	SST₂ > SST₃	33.9 ± 4%^*	9
l-796,778	SST₃	5.2 ± 3.4^* ^, ^**	5
J-2156	SST₄	21.8 ± 3%^*	10
l-803,087	SST₄	2.1 ± 5.7%^* ^, ^**	8
Octreotide + J-2156	SST₂ + SST₄	47.0 ± 5	6
SST + SRA880 ^a	All but SST₁	47.0 ± 2	7
SST + ACQ090 ^b	All but SST₃	46 ± 5	6

Concentration is 1 μm for all drugs except when octreotide and J-2156 are coapplied (0.5 μm each).
↵ ^aSST₁-selective antagonist.
↵ ^bSST₃-selective antagonist.
↵*Significantly different from SST alone (p < 0.05; unpaired t test);
↵**no significant inhibition of burst rate (p > 0.05; paired t test).

The Journal of Neuroscience Society for Neuroscience

Somatostatin Receptor Subtype 4 Couples to the M-Current to Regulate Seizures